XOMA
Yahoo Finance • 6 days ago
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeov... Full story
Yahoo Finance • 8 days ago
XOMA Preferred Shares Series A declares $0.5391 dividend
* XOMA Preferred Shares Series A (NASDAQ:XOMAP [https://seekingalpha.com/symbol/XOMAP]) declares $0.5391/share quarterly dividend [https://seekingalpha.com/pr/20239358-xoma-royalty-declares-quarterly-preferred-stock-dividends], in line w... Full story
Yahoo Finance • 8 days ago
XOMA Royalty Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulati... Full story
Yahoo Finance • 27 days ago
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will pres... Full story
Yahoo Finance • last month
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corporation (Nasdaq: XOMA), a biotechnology royal... Full story
Yahoo Finance • last month
WALTHAM, DUBLIN, EMERYVILLE - Mural Oncology agrees to acquisition by XOMA Royalty subsidiary
WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif. - Mural Oncology plc (NASDAQ:MURA) has entered into a definitive agreement to be acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty Corporation (NASDAQ:XOMA), for bet... Full story
Yahoo Finance • last month
HILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX
NEW YORK CITY and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of HilleVax, Inc. (Na... Full story
Yahoo Finance • 2 months ago
XOMA earnings beat by $0.64, revenue topped estimates
Investing.com - XOMA (NASDAQ: XOMA) reported second quarter EPS of $0.44, $0.64 better than the analyst estimate of $-0.20. Revenue for the quarter came in at $13.13M versus the consensus estimate of $8.67M. XOMA’s stock price closed at $... Full story
Yahoo Finance • 2 months ago
XOMA GAAP EPS of $0.44 beats by $0.59, revenue of $13.13M beats by $3.74M
* XOMA press release [https://seekingalpha.com/pr/20199201-xoma-royalty-reports-second-quarter-and-year-to-date-2025-financial-results-and-highlights] (NASDAQ:XOMA [https://seekingalpha.com/symbol/XOMA]): Q2 GAAP EPS of $0.44 beats by $0... Full story
Yahoo Finance • 2 months ago
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
XOMA Royalty Corporation Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recent... Full story
Yahoo Finance • 2 months ago
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
BALA CYNWYD, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story
Yahoo Finance • 2 months ago
XOMA Royalty to acquire cancer drug developer LAVA Therapeutics
[Wooden blocks with text M and A on light blue paper, business concept. MA - short for mergers and acquisitions] Biotech royalty aggregator XOMA Royalty (NASDAQ:XOMA [https://seekingalpha.com/symbol/XOMA]) has agreed to acquire cancer dru... Full story
Yahoo Finance • 2 months ago
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) announced today they have ent... Full story
Yahoo Finance • 2 months ago
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
BOSTON and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX) and XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) announced today they have entered into a definitive... Full story
Yahoo Finance • 3 months ago
Turnstone Biologics to be acquired by XOMA Royalty
[Wooden blocks with text M and A on light blue paper, business concept. MA - short for mergers and acquisitions] * XOMA Royalty (NASDAQ:XOMA [https://seekingalpha.com/symbol/XOMA]), a biotech royalty acquirer based in Emeryville, Califo... Full story
Yahoo Finance • 3 months ago
XOMA Royalty to acquire Turnstone Biologics for $0.34 per share
EMERYVILLE/SAN DIEGO - XOMA Royalty Corporation (NASDAQ:XOMA), a biotechnology royalty aggregator with a market capitalization of $327 million and impressive gross profit margins of 90%, announced today it will acquire Turnstone Biologics... Full story
Yahoo Finance • 3 months ago
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) and Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX) today announced that they have en... Full story
Yahoo Finance • 4 months ago
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focus... Full story
Yahoo Finance • 5 months ago
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be fea... Full story
Yahoo Finance • 6 months ago
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contin... Full story
